Aug, 03, 2022

Soleo Health One of a Select Few Specialty Pharmacies Chosen to Provide Cuvitru® to Patients

Addition of Treatment for Primary Immunodeficiency Rounds Out Company’s Broad Immunoglobulin Offering

FRISCO, Texas, August 3, 2022 – Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been chosen as one of a select few specialty pharmacies to provide Cuvitru® to patients nationwide.

Administered subcutaneously, Cuvitru is manufactured by Takeda Pharmaceutical Company Ltd. Cuvitru replaces antibodies not working correctly or are missing from one’s body to help protect it against infection. CUVITRU is for treating primary immunodeficiency (PI) in adults and children two years of age and older.

“Access to Cuvitru rounds out Soleo Health’s comprehensive immunoglobulin (Ig) therapy offering. With this addition, Soleo Health now offers all FDA-approved Ig therapies available in the marketplace today. We continue to cater to the needs of our patients and prescribers by broadening our therapeutic portfolio and providing exceptional care,” noted Drew Walk, Soleo Health’s chief executive officer.

About Soleo Health

Soleo Health is an innovative national provider of complex specialty pharmacy services administered in the home or at alternate sites of care. Soleo Health’s interdisciplinary clinical team comprises highly experienced pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. The Company optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences.

Soleo Health operates 21 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission.

Visit or connect with Soleo Health on LinkedIn, Facebook and Twitter for more information.